<DOC>
	<DOCNO>NCT00479232</DOCNO>
	<brief_summary>This study evaluate safety tolerability vorinostat combination decitabine well vivo molecular biological effect vorinostat patient refractory relapse Acute Myelogenous Leukemia ( AML ) intermediate high risk define International Prognostic Scoring System ( IPSS ) Myelodysplastic Syndrome ( MDS ) . Participants Acute Myelogenous Leukemia Myelodysplastic Syndrome eligible .</brief_summary>
	<brief_title>Phase I Trial Vorinostat ( MK-0683 , SAHA ) Combination With Decitabine Patients With AML MDS ( MK-0683-055 EXT1 )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patient least 18 year old refractory/relapsed AML If untreated AML , patient old 60 year old candidate standard chemotherapy Patient least 4 week prior treatment recover prior treatment side effect Patient know liver kidney problem Patient know reason receive transfusion blood clot cell ( platelet ) Patient able swallow capsule Patients male female willing practice birth control study Patient receive prior treatment valproic acid , decitabine azacitidine Being le 18 year age patient untreated AML 60 year age Patient woman pregnant breastfeeding . Patient active infection require antibiotic Patient uncontrolled illness include limited following : heart problem ( congestive heart failure , unstable angina pectoris , cardiac arrhythmia ) , inflammation pancreas ; mental social condition may interfere patient follow study procedure Patient know human immunodeficiency virus ( HIV ) infection HIVrelated malignancy . Patient known history hepatitis B C infection Patient currently another active cancer certain type skin cancer Patient heterosexual able child unwilling practice birth control study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myelocytic</keyword>
	<keyword>Acute Myelodysplastic Syndromes</keyword>
</DOC>